The All India Institute of Medical Sciences (AIIMS) Ethics Committee on Saturday gave its authorization for the human clinical trial of Covaxin, a coronavirus vaccine candidate.
From today on, the hospital will continue to enroll healthier individuals, news agency PTI announced.AIIMS-Delhi is one of the 12 sites chosen by the Indian Council for Medical Research (ICMR) for Phase I and Phase II human Covaxin trials. In Phase I, the vaccine will be tested on 375 volunteers and a limit of 100 would be AIIMS.
Volunteers are needed for the Covid-19 Vaccine clinical trial at AIIMS Delhi. Healthy patients with no comorbid conditions and with no record of COVID-19, over 18 years of age and under 55 years of age, will be eligible to enroll in a randomized, double-blind, placebo-controlled clinical trial.
India’s first indigenous Covid-19 vaccine candidate Covaxin is being developed by Hyderabad-based Bharat Biotech in cooperation with the ICMR and the National Institute of Virology (NIV).